956 reports of this reaction
3.8% of all BIMEKIZUMAB reports
#6 most reported adverse reaction
OFF LABEL USE is the #6 most commonly reported adverse reaction for BIMEKIZUMAB, manufactured by UCB, Inc.. There are 956 FDA adverse event reports linking BIMEKIZUMAB to OFF LABEL USE. This represents approximately 3.8% of all 25,281 adverse event reports for this drug.
Patients taking BIMEKIZUMAB who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among BIMEKIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for BIMEKIZUMAB:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 956 FDA reports for BIMEKIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 3.8% of all adverse event reports for BIMEKIZUMAB, making it a notable side effect.
If you experience off label use while taking BIMEKIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.